Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

New phase III psoriasis data show rapid, significant skin clearance and convenient administration with Novartis AG' secukinumab


Saturday, 22 Mar 2014 02:15am EDT 

Novartis AG:Announces results from pivotal phase III FEATURE and JUNCTURE studies showing secukinumab (AIN457), interleukin-17A (IL-17A) inhibitor, demonstrated consistent high efficacy when administered with convenient pre-filled syringe (PFS) or autoinjector/pen (AI).These results, along with patient-reported outcomes showing high patient satisfaction with PFS and AI 3,4, are being presented for first time at 72nd annual meeting of the American Academy of Dermatology (AAD) in Denver, USA.In both studies more secukinumab 300 mg patients experienced almost clear skin, described as Psoriasis Area and Severity Index 90 (PASI 90), at Week 12 (60.3 pct. for FEATURE and 55 pct. for JUNCTURE, p <0.0001) compared to placebo.PASI 90 is considered best evidence of efficacy, and a more robust measure of the extent of skin clearance compared to standard efficacy measures that have been used in most psoriasis clinical studies, such as PASI 75. 

Company Quote

89.04
0.44 +0.50%
11:31am EDT